These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 24674779)

  • 1. Changes in B and T-cell subsets and NMO-IgG levels after immunoglobulins and rituximab treatment for an acute attack of neuromyelitis optica.
    de Andrés C; Teijeiro R; Saiz A; Fernández P; Sánchez-Ramón S
    Neurologia; 2015 Jun; 30(5):276-82. PubMed ID: 24674779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis.
    Quan C; Yu H; Qiao J; Xiao B; Zhao G; Wu Z; Li Z; Lu C
    Mult Scler; 2013 Mar; 19(3):289-98. PubMed ID: 22864301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid.
    Marignier R; Ruiz A; Cavagna S; Nicole A; Watrin C; Touret M; Parrot S; Malleret G; Peyron C; Benetollo C; Auvergnon N; Vukusic S; Giraudon P
    J Neuroinflammation; 2016 May; 13(1):111. PubMed ID: 27193196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunopathogenesis of neuromyelitis optica.
    Levy M; Wildemann B; Jarius S; Orellano B; Sasidharan S; Weber MS; Stuve O
    Adv Immunol; 2014; 121():213-42. PubMed ID: 24388217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
    Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
    J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study.
    Cohen M; Romero G; Bas J; Ticchioni M; Rosenthal M; Lacroix R; Brunet C; Rico A; Pelletier J; Audoin B; Lebrun C
    J Neurol Sci; 2017 Feb; 373():335-338. PubMed ID: 28131216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures.
    Jarius S; Paul F; Franciotta D; Ruprecht K; Ringelstein M; Bergamaschi R; Rommer P; Kleiter I; Stich O; Reuss R; Rauer S; Zettl UK; Wandinger KP; Melms A; Aktas O; Kristoferitsch W; Wildemann B
    J Neurol Sci; 2011 Jul; 306(1-2):82-90. PubMed ID: 21550068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.
    Takahashi T; Fujihara K; Nakashima I; Misu T; Miyazawa I; Nakamura M; Watanabe S; Shiga Y; Kanaoka C; Fujimori J; Sato S; Itoyama Y
    Brain; 2007 May; 130(Pt 5):1235-43. PubMed ID: 17449477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
    Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
    J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica.
    Jarius S; Aboul-Enein F; Waters P; Kuenz B; Hauser A; Berger T; Lang W; Reindl M; Vincent A; Kristoferitsch W
    Brain; 2008 Nov; 131(Pt 11):3072-80. PubMed ID: 18945724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy.
    Quan C; ZhangBao J; Lu J; Zhao C; Cai T; Wang B; Yu H; Qiao J; Lu C
    J Neuroimmunol; 2015 May; 282():45-53. PubMed ID: 25903728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuromyelitis optica.
    Matiello M; Jacob A; Wingerchuk DM; Weinshenker BG
    Curr Opin Neurol; 2007 Jun; 20(3):255-60. PubMed ID: 17495617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
    Rostásy K; Mader S; Hennes EM; Schanda K; Gredler V; Guenther A; Blaschek A; Korenke C; Pritsch M; Pohl D; Maier O; Kuchukhidze G; Brunner-Krainz M; Berger T; Reindl M
    Mult Scler; 2013 Jul; 19(8):1052-9. PubMed ID: 23257621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study.
    Kovacs KT; Kalluri SR; Boza-Serrano A; Deierborg T; Csepany T; Simo M; Rokusz L; Miseta A; Alcaraz N; Czirjak L; Berki T; Molnar T; Hemmer B; Illes Z
    Mult Scler; 2016 Aug; 22(9):1192-201. PubMed ID: 26514978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuromyelitis optica pathogenesis and aquaporin 4.
    Graber DJ; Levy M; Kerr D; Wade WF
    J Neuroinflammation; 2008 May; 5():22. PubMed ID: 18510734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cerebrospinal fluid immunoglobulin transcriptome and proteome in neuromyelitis optica reveals central nervous system-specific B cell populations.
    Kowarik MC; Dzieciatkowska M; Wemlinger S; Ritchie AM; Hemmer B; Owens GP; Bennett JL
    J Neuroinflammation; 2015 Jan; 12():19. PubMed ID: 25626447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aquaporin-4 antibodies, CNS acidosis and neuromyelitis optica: a potential link.
    Jarius S; Wildemann B
    Med Hypotheses; 2013 Dec; 81(6):1090-5. PubMed ID: 24182872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study.
    Cabre P; Mejdoubi M; Jeannin S; Merle H; Plumelle Y; Cavillon G; Smadja D; Marignier R;
    J Neurol; 2018 Apr; 265(4):917-925. PubMed ID: 29455361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualized rituximab treatment for relapsing neuromyelitis optica: a pediatric case report.
    He D; Yu Y; Yan W; Dai Q; Xu Z; Chu L
    Pediatr Neurol; 2014 Aug; 51(2):255-8. PubMed ID: 25079575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neuromyelitis optica: a separate disease entity associated with aquaporin-4-antibodies].
    Jordan B; Eger K; Kornhuber ME; Zierz S
    Fortschr Neurol Psychiatr; 2008 Jan; 76(1):21-7. PubMed ID: 18189220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.